NETRIS Pharma
  • Our company
    • About us
    • Our team
    • Scientific Advisory Board
    • Clinical Advisors
  • Our Science
    • Concept and Focus on oncology
    • Therapeutic strategy
  • Portfolio
    • Pipeline
    • Netrin-1 Lead Program
  • Publications
  • News
  • Contact us
  • Our company
    • About us
    • Our team
    • Scientific Advisory Board
    • Clinical Advisors
  • Our Science
    • Concept and Focus on oncology
    • Therapeutic strategy
  • Portfolio
    • Pipeline
    • Netrin-1 Lead Program
  • Publications
  • News
  • Contact us

Discover our news

31 décembre 2020
9

NETRIS Pharma Announces First Patient Dosed in Phase Ib/II

By Netris Pharma | Actualités, News

NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA®   December 31, 2020 LYON, France – NETRIS Pharma, a…

Read More
26 décembre 2020
8

Bio Partnering @ JPM – January 2021

By Netris Pharma | Actualités, News

NETRIS Pharma will attend the Bio Partnering  @ JPM conference that will take place Virtual  (Jan 11th-15th, 2021). Our team members will be pleased to meet with you and discuss…

Read More
23 décembre 2020
9

NETRIS Pharma successfully completes a €16.1m Series A

By Netris Pharma | Actualités, News

December 23rd, 2020 – Geneva – Switzerland and Lyon – France NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m…

Read More
5 mai 2020
8

Press release – Clinical Trial Collaboration Agreement with MSD (Merck US)

By Netris Pharma | Actualités, News

NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate…

Read More
28 juin 2019
0

ANR granted the RHU DEPGYN project

By Netris Pharma | Actualités, News

NETRIS Pharma is pleased to announce that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches…

Read More
9 janvier 2018
0

Pr. Bernet appointed as Knight of the Legion of Honor

By Netris Pharma | Actualités, News

The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…

Read More

Contact

NETRIS PHARMA
Centre Léon Bérard
28 rue Laennec
69008 LYON
France
+33 (0)4 78 78 29 53
contact@netrispharma.com

Links

  • Mentions légales
  • Careers

News

  • NETRIS Pharma Announces First Patient Dosed in Phase Ib/II 31 décembre 2020
  • Bio Partnering @ JPM – January 2021 26 décembre 2020
  • NETRIS Pharma successfully completes a €16.1m Series A 23 décembre 2020
  • Press release – Clinical Trial Collaboration Agreement with MSD (Merck US) 5 mai 2020

Copyright © 2016 NETRIS Pharma | Sitemap page

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.OK